The agreement covers joint work on commercializing Teijin’s SYNFOLIUMⓇ heart repair patch in India and introducing BioVaram’s exosome-based therapeutics and collagen biomaterials in Japan
In a significant move to bridge medical innovation across Asia, Teijin Limited, a technology-led global group based in Japan, has entered into a strategic partnership with BioVaram, the biotechnology arm of Hyderabad-based UR Advanced Therapeutics Pvt Ltd (URAT). The two companies have signed a formal business alliance agreement to advance the availability and development of regenerative medicine products and implantable medical devices in India and Japan.
The agreement is a dual-track collaboration that allows Teijin to evaluate and introduce BioVaram’s novel regenerative medicine innovations into Japan, while enabling BioVaram to bring select products from Teijin’s healthcare portfolio into the Indian clinical and regulatory ecosystem.
One of the key components of this alliance is the proposed regulatory approval and commercialization of SYNFOLIUMⓇ, a bioabsorbable cardiovascular patch developed by Teijin Medical Technologies Co., Ltd., a group company of Teijin Limited. Designed for tissue repair in cardiovascular surgeries, this device is now being evaluated for market entry in India. The partnership aims to expedite this process through local clinical validation and regulatory compliance.
Equally important to the alliance is the potential expansion of Japan Tissue Engineering Co., Ltd. (J-TEC) products into India. J-TEC, a subsidiary of the Teijin Group, is one of Japan’s leading names in regenerative medicine. Their offerings in skin, cartilage, and tissue-engineered cellular products are currently available only in the Japanese market but are now being explored for introduction to India through this collaboration.
From the Indian side, BioVaram will evaluate the development and potential approval pathways for some of its flagship innovations in Japan. This includes exosome-based diagnostics and therapeutics, extracellular matrix mimics, and bio-derived materials such as Type I atelocollagen, which are key ingredients in tissue engineering. These products will be positioned for potential development in collaboration with Japanese manufacturing and distribution channels, and technical integration will be a core area of joint planning.
Commenting on the partnership, Dr. Takayuki Nakano, Mission Executive and General Manager of the Regenerative Medicine & Implantable Medical Device Division at Teijin Limited, said the agreement represents a significant step in the group’s international expansion. “By combining the exceptional technological capabilities and expertise of both companies across the distinct healthcare markets of Japan and India, we are confident in our ability to deliver meaningful therapies that address long-standing gaps in care. This partnership builds on Teijin’s commitment to globalizing its regenerative medicine business.”
Echoing the sentiment, Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, described the partnership as a milestone in BioVaram’s global journey. “This agreement reinforces our vision to transform India into a centre of excellence for regenerative medicine. Through collaboration with Teijin, we expand our R&D capabilities, scale our manufacturing, and gain access to a healthcare market that is both deeply advanced and open to innovation.”
Founded in 2018 and headquartered in Hyderabad, BioVaram has rapidly earned recognition as one of India’s most promising biotechnology companies in the space of regenerative medicine and cellular therapeutics. It was named a “Top 5 Startup” at BioAsia 2024 and is known for its in-house development of AI-designed peptides, therapeutic exosomes, and a proprietary portfolio of collagen-based scaffolds and ECM substitutes.
On the Japanese side, Teijin brings a long-standing legacy in medical and material sciences. Established in 1918 and listed on the Tokyo Stock Exchange (TSE: 3401), Teijin Limited operates across high-performance materials and healthcare, with over 170 group companies globally. Its healthcare division includes Teijin Medical Technologies, Teijin Regenet, and J-TEC, all working across regenerative therapies, CDMO services, and implantable devices.
In 2022, Teijin consolidated these businesses into a dedicated division focused on regenerative medicine, setting a fiscal 2030 target of JPY 20 billion in global revenue from this vertical. The alliance with BioVaram is expected to play a crucial role in fulfilling this vision by adding scalable, export-ready technologies from India into Teijin’s innovation and commercialization pipeline.
As part of the roadmap, the companies will jointly assess the regulatory pathways, product compatibility, technical integration, and manufacturing feasibility for several co-developed initiatives. These include cell and gene therapy, bioengineered skin and tissue products, and advanced biomaterials for surgical applications.
The collaboration also reflects a broader shift toward cross-border innovation in the healthcare sector. With Japan’s super-ageing population and India’s fast-growing biotech capabilities, the alliance between Teijin and BioVaram brings together two ecosystems that are distinct yet complementary.
As regulatory consultations begin and feasibility studies move forward, both companies will continue to co-develop products that meet shared standards of efficacy, patient safety, and ethical manufacturing.
This partnership signals not only a new era of product development and global expansion but also a mutual commitment to innovation that is sustainable, accessible, and deeply rooted in science.
At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTub
1 Comment